QRG Capital Management Inc. Decreases Holdings in Genmab A/S (NASDAQ:GMAB)

QRG Capital Management Inc. decreased its position in shares of Genmab A/S (NASDAQ:GMAB) by 3.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,436 shares of the company’s stock after selling 1,037 shares during the quarter. QRG Capital Management Inc.’s holdings in Genmab A/S were worth $718,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. US Bancorp DE raised its position in shares of Genmab A/S by 16.0% during the 3rd quarter. US Bancorp DE now owns 171,669 shares of the company’s stock worth $4,185,000 after purchasing an additional 23,723 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Genmab A/S by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,064 shares of the company’s stock worth $197,000 after purchasing an additional 3,137 shares during the last quarter. Legacy Wealth Asset Management LLC raised its position in shares of Genmab A/S by 1.1% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after purchasing an additional 471 shares during the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Genmab A/S during the 3rd quarter worth approximately $699,000. Finally, Mount Yale Investment Advisors LLC acquired a new position in shares of Genmab A/S during the 3rd quarter worth approximately $192,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Down 0.1 %

Shares of NASDAQ GMAB opened at $23.08 on Friday. Genmab A/S has a 52-week low of $21.90 and a 52-week high of $32.89. The firm has a fifty day moving average of $24.39 and a 200-day moving average of $26.41. The stock has a market capitalization of $15.27 billion, a PE ratio of 22.41, a P/E/G ratio of 0.66 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 14.73% and a net margin of 23.49%. The business had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Equities research analysts expect that Genmab A/S will post 1.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GMAB has been the subject of several research reports. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Truist Financial cut their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.